Wen-Jing Shen1, Dong-Qiu Dai, Yue Teng, Hong-Bo Liu. 1. Department of Surgical Oncology, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China.
Abstract
AIM: To investigate the changes of methylation state and expression of RASSF1A gene in human gastric cancer cell lines SGC7901 and BGC823 which were treated in vitro with demethlylating agent 5-Aza-CdR in combination with histone deacetylase inhibitor NaB. METHODS: After SGC7901 and BGC823 cells were treated with 5-Aza-CdR and/or NaB, the methylation state of RASSF1A gene was detected by methylation-specific PCR, and the changes in expression of mRNA and protein level of RASSF1A gene were observed by RT-PCR and Western-blotting before and after drug treatment. RESULTS: Hypermethylation was detected in the promoter region of RASSF1A gene in both SGC7901 and BGC823 cells, and there was no expression of this gene at both mRNA and protein level. After treatment with 5-Aza-CdR, demethylation occurred in the promoter region of RASSF1A gene, which subsequently induced re-expression of this gene. The treatment with NaB alone showed no effect on the methylation state and expression of RASSF1A gene. The combined treatment of 5-Aza-CdR and NaB induced complete demethylation of RASSF1A gene, leading to a significantly higher re-expression of the mRNA and protein of RASSF1A than those treated with 5-Aza-CdR alone (P<0.05). CONCLUSION: Hypermethylation in the promoter region is related to inactivation of RASSF1A gene in human gastric cancer cell lines SGC7901 and BGC823, while demethlylating agent 5-Aza-CdR can reverse the methylation state of RASSF1A gene and induce its re-expression. Histone deacetylase inhibitor NaB had a synergistic effect with 5-Aza-CdR in both demethylation and gene transcriptional regulation.
AIM: To investigate the changes of methylation state and expression of RASSF1A gene in humangastric cancer cell lines SGC7901 and BGC823 which were treated in vitro with demethlylating agent 5-Aza-CdR in combination with histone deacetylase inhibitor NaB. METHODS: After SGC7901 and BGC823 cells were treated with 5-Aza-CdR and/or NaB, the methylation state of RASSF1A gene was detected by methylation-specific PCR, and the changes in expression of mRNA and protein level of RASSF1A gene were observed by RT-PCR and Western-blotting before and after drug treatment. RESULTS: Hypermethylation was detected in the promoter region of RASSF1A gene in both SGC7901 and BGC823 cells, and there was no expression of this gene at both mRNA and protein level. After treatment with 5-Aza-CdR, demethylation occurred in the promoter region of RASSF1A gene, which subsequently induced re-expression of this gene. The treatment with NaB alone showed no effect on the methylation state and expression of RASSF1A gene. The combined treatment of 5-Aza-CdR and NaB induced complete demethylation of RASSF1A gene, leading to a significantly higher re-expression of the mRNA and protein of RASSF1A than those treated with 5-Aza-CdR alone (P<0.05). CONCLUSION: Hypermethylation in the promoter region is related to inactivation of RASSF1A gene in humangastric cancer cell lines SGC7901 and BGC823, while demethlylating agent 5-Aza-CdR can reverse the methylation state of RASSF1A gene and induce its re-expression. Histone deacetylase inhibitor NaB had a synergistic effect with 5-Aza-CdR in both demethylation and gene transcriptional regulation.
Authors: X Yang; A T Ferguson; S J Nass; D L Phillips; K A Butash; S M Wang; J G Herman; N E Davidson Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701
Authors: Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Alma Chavez-Blanco; Alma Revilla-Vazquez; Luis Benitez-Bribiesca; Alfonso Duenas-González Journal: J Transl Med Date: 2006-08-07 Impact factor: 5.531
Authors: Sarandeep S S Boyanapalli; Wenji Li; Francisco Fuentes; Yue Guo; Christina N Ramirez; Ximena-Parades Gonzalez; Douglas Pung; Ah-Ng Tony Kong Journal: Pharmacol Res Date: 2016-11-03 Impact factor: 7.658
Authors: C Christofer Juhlin; Nimrod B Kiss; Andrea Villablanca; Felix Haglund; Jörgen Nordenström; Anders Höög; Catharina Larsson Journal: PLoS One Date: 2010-03-01 Impact factor: 3.240
Authors: Hang Joo Cho; Sin Young Kim; Kee Hwan Kim; Won Kyung Kang; Ji Il Kim; Seong Tack Oh; Jeong Soo Kim; Chang Hyeok An Journal: World J Surg Oncol Date: 2009-05-21 Impact factor: 2.754